A Pancreatic Cancer Patient-Derived Xenograft Model for Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes.
作者信息
Leone Valentina, Peschke Katja, Reichert Maximilian
机构信息
Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Translational Pancreatic Cancer Research Center, Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
出版信息
Gastro Hep Adv. 2022 Aug 31;1(6):1122-1123. doi: 10.1016/j.gastha.2022.08.008. eCollection 2022.
Abstract
摘要
相似文献
1
A Pancreatic Cancer Patient-Derived Xenograft Model for Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes.
Gastro Hep Adv. 2022 Aug 31;1(6):1122-1123. doi: 10.1016/j.gastha.2022.08.008. eCollection 2022.
2
Genetics and Therapeutic Responses to Tumor-Infiltrating Lymphocyte Therapy of Pancreatic Cancer Patient-Derived Xenograft Models.
Gastro Hep Adv. 2022 Jul 15;1(6):1037-1048. doi: 10.1016/j.gastha.2022.07.006. eCollection 2022.
3
An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
Gynecol Oncol. 2020 Jan;156(1):222-232. doi: 10.1016/j.ygyno.2019.10.011. Epub 2019 Dec 7.
4
[Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes].
Nihon Gan Chiryo Gakkai Shi. 1990 May 20;25(5):978-89.
5
Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
Gynecol Oncol. 2003 May;89(2):271-80. doi: 10.1016/s0090-8258(03)00083-0.
6
Evaluation of the tumoricidal efficacy of adoptive cell transfer using hepatocellular carcinoma-derived organoids.
J Gastrointest Oncol. 2022 Apr;13(2):732-743. doi: 10.21037/jgo-21-715.
7
Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy.
Cancer Biol Ther. 2009 Jan;8(1):66-72. doi: 10.4161/cbt.8.1.7131. Epub 2009 Jan 4.
8
Human accessory cells activate fresh, normal, tumor-distant T lymphocytes but not tumor-infiltrating T lymphocytes to lyse autologous tumor cells in a primary cytotoxic T lymphocyte assay in renal cell carcinoma.
Eur Urol. 2001 Oct;40(4):427-33. doi: 10.1159/000049811.
9
Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
Gynecol Oncol. 2018 Aug;150(2):361-369. doi: 10.1016/j.ygyno.2018.05.024. Epub 2018 May 24.
10
A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma.
Oncotarget. 2015 Dec 1;6(38):41339-49. doi: 10.18632/oncotarget.5463.
本文引用的文献
1
Cancer statistics, 2022.
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
2
Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
BMC Cancer. 2021 Nov 10;21(1):1197. doi: 10.1186/s12885-021-08911-4.
3
Pancreatic Cancer and Immunotherapy: A Clinical Overview.
Cancers (Basel). 2021 Aug 17;13(16):4138. doi: 10.3390/cancers13164138.
4
Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review).
Int J Mol Med. 2021 Jun;47(6). doi: 10.3892/ijmm.2021.4930. Epub 2021 Apr 13.
5
Estimated Projection of US Cancer Incidence and Death to 2040.
JAMA Netw Open. 2021 Apr 1;4(4):e214708. doi: 10.1001/jamanetworkopen.2021.4708.
6
The Outcome of TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic Growth Capacity between T-Cell Clones.
Clin Cancer Res. 2020 Aug 15;26(16):4289-4301. doi: 10.1158/1078-0432.CCR-19-3845. Epub 2020 Apr 17.
7
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.
Lancet Oncol. 2020 Apr;21(4):508-518. doi: 10.1016/S1470-2045(20)30074-7. Epub 2020 Mar 2.
8
Checkpoint inhibitors in pancreatic cancer.
Cancer Treat Rev. 2019 Aug;78:17-30. doi: 10.1016/j.ctrv.2019.06.005. Epub 2019 Jun 27.
9
Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.
Pharmacol Ther. 2019 Sep;201:202-213. doi: 10.1016/j.pharmthera.2019.05.012. Epub 2019 May 31.
10
Immunotherapy in colorectal cancer: rationale, challenges and potential.
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375. doi: 10.1038/s41575-019-0126-x.
Zotero 插件